Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NCT01019434

Last updated date
Study Location
UZ Leuven
Leuven, , , Belgium
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Brain and Central Nervous System Tumors
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-120 years

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Brain and Central Nervous System TumorsRadiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
NCT01019434
  1. Leuven,
  2. Nantes-Saint Herblain,
  3. Paris,
  4. Freiburg,
  5. Heidelberg,
  6. Bologna,
  7. Den Haag,
  8. Rotterdam,
  9. Badalona,
  10. Bellinzona,
  11. Zurich,
  12. Bebington, Wirral
  13. Edinburgh,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Brain and Central Nervous System TumorsPrinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00004200
  1. La Jolla, California
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Brain and Central Nervous System TumorsLeflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse
NCT00003775
  1. Phoenix, Arizona
  2. Los Angeles, California
  3. Denver, Colorado
  4. Miami Beach, Florida
  5. Chicago, Illinois
  6. Indianapolis, Indiana
  7. Iowa City, Iowa
  8. Boston, Massachusetts
  9. Ann Arbor, Michigan
  10. Detroit, Michigan
  11. Albany, New York
  12. Bronx, New York
  13. New York, New York
  14. New York, New York
  15. Chapel Hill, North Carolina
  16. Cincinnati, Ohio
  17. Columbus, Ohio
  18. Pittsburgh, Pennsylvania
  19. Providence, Rhode Island
  20. Dallas, Texas
  21. Houston, Texas
  22. Milwaukee, Wisconsin
  23. Edmonton, Alberta
  24. Vancouver, British Columbia
  25. London, Ontario
  26. Toronto, Ontario
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Brain and Central Nervous System TumorsSU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme
NCT00003293
  1. Phoenix, Arizona
  2. Tucson, Arizona
  3. Los Angeles, California
  4. Los Angeles, California
  5. Los Angeles, California
  6. San Francisco, California
  7. Denver, Colorado
  8. Miami Beach, Florida
  9. Tampa, Florida
  10. Augusta, Georgia
  11. Chicago, Illinois
  12. Indianapolis, Indiana
  13. Iowa City, Iowa
  14. Boston, Massachusetts
  15. Worcester, Massachusetts
  16. Ann Arbor, Michigan
  17. Detroit, Michigan
  18. Omaha, Nebraska
  19. Albany, New York
  20. Bronx, New York
  21. New York, New York
  22. New York, New York
  23. Chapel Hill, North Carolina
  24. Cincinnati, Ohio
  25. Columbus, Ohio
  26. Pittsburgh, Pennsylvania
  27. Providence, Rhode Island
  28. Nashville, Tennessee
  29. Dallas, Texas
  30. Houston, Texas
  31. Seattle, Washington
  32. Milwaukee, Wisconsin
  33. Edmonton, Alberta
  34. London, Ontario
  35. Toronto, Ontario
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Official Title  ICMJE Radiation Therapy and Concurrent Plus Adjuvant Temsirolimus (CCI-779) Versus Chemo-Irradiation With Temozolomide in Newly Diagnosed Glioblastoma Without Methylation of the MGMT Gene Promoter - A Randomized Multicenter, Open-Label, Phase II Study.
Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with temsirolimus or temozolomide in treating patients with glioblastoma.

PURPOSE: This randomized phase II trial is studying giving radiation therapy together with temsirolimus to see how well it works compared with giving radiation therapy together with temozolomide in treating patients with newly diagnosed glioblastoma.

Detailed Description

OBJECTIVES:

Primary

  • Document the activity profile of temsirolimus by the evaluation of overall survival at 1 year in patients with newly diagnosed glioblastoma multiforme, without methylation of the MGMT gene promoter, treated with temsirolimus before and concomitantly with radiotherapy, followed by temsirolimus maintenance therapy.

Secondary

  • Investigate safety and tolerability of this therapy regimen in these patients.
  • Assess progression-free survival and overall survival of these patients.
  • Assess biomarkers in the tumor tissue relevant to temsirolimus and disease state, and their correlation to clinical outcome in these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to institution, age in years (< 50 vs ? 50), Karnofsky performance status (PS) (< 80% vs ? 80%) OR ECOG PS (0 or 1 vs 2), and corticosteroid use (yes vs no). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Within 7 weeks after surgery or open biopsy, patients undergo radiotherapy 5 days a week for 6 weeks and receive oral temozolomide concurrently once daily for 6 weeks. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients receive adjuvant oral temozolomide once daily on days 1-5. Treatment with adjuvant temozolomide repeats every 28 days for up to 12 courses in the absence of disease progression and unacceptable toxicity.
  • Arm II: Within 7 weeks after surgery or open biopsy, patients undergo radiotherapy 5 days a week for 6 weeks. Patients also receive temsirolimus IV over 30-60 minutes once weekly beginning 7 days before initiation of radiotherapy. After completion of chemoradiotherapy, patients receive maintenance temsirolimus IV once weekly in the absence of disease progression and unacceptable toxicity.

Frozen tumor biopsies or paraffin-embedded tumor material obtained from surgery or open biopsy and blood samples are collected for analysis of molecular markers, determination of the methylation status of the MGMT gene promoter (before randomization and at a later time), and other studies.

After completion of study therapy, patients are followed every 3 months.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Brain and Central Nervous System Tumors
Intervention  ICMJE
  • Drug: temozolomide
    TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
  • Drug: temsirolimus
    CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
Study Arms  ICMJE
  • Temozolomide
    TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
    Intervention: Drug: temozolomide
  • Experimental: Temsirolimus
    CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
    Intervention: Drug: temsirolimus
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 11, 2016)
111
Original Estimated Enrollment  ICMJE
 (submitted: November 24, 2009)
108
Actual Study Completion Date  ICMJE March 2014
Actual Primary Completion Date December 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

DISEASE CHARACTERISTICS:

  • Histologically confirmed (by open brain biopsy or from a neurosurgical resection of the tumor) supratentorial glioblastoma multiforme (GBM)

    • WHO grade IV disease
    • Newly diagnosed disease
  • Must provide demonstration of an unmethylated MGMT-promoter
  • At least 2 weeks and no more than 6 weeks since surgery or open biopsy
  • Tumor tissue specimens (paraffin-embedded and/or frozen) from the GBM surgery or open biopsy must be available for central pathology review, MGMT status determination, and exploratory analysis of PI3-K/Akt/mTOR targets (P70S6K)

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-2
  • Life expectancy ? 12 weeks
  • WBC ? 3.0 x 10^9/L
  • Absolute neutrophil count ? 1.5 x10^9/L
  • Platelet count ? 75.0 x 10^9/L
  • Hemoglobin ? 10.0 g/dL
  • Bilirubin ? 1.5 times the upper limit of normal (ULN)
  • Alkaline phosphatase ? 2.5 x ULN
  • AST and/or ALT ? 2.5 x ULN
  • Serum creatinine < 1.5 x ULN
  • PT and PTT normal
  • Negative pregnancy test
  • Not pregnant or nursing
  • Fertile patients must use highly effective contraception
  • No ischemic heart disease in the past 6 months
  • 12-lead ECG normal
  • No history of stroke
  • No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or nonmelanoma skin cancer (with no subsequent evidence of recurrence)
  • No serious concurrent systemic disorder including any of the following that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol:

    • Active infection
    • HIV infection
    • Cardiac disease
    • QTc prolongation > 450/470 msec (males/females)
    • No patients with a congenital long-QT-syndrome in their own or family medical history, unless eligible at the investigator's discretion
  • No known hypersensitivity to the study treatment
  • No known hypersensitivity to antihistamines or other medical reason that prohibits the intake of antihistamines
  • No current alcohol dependence or drug abuse
  • No legal incapacity or limited legal capacity
  • Able to undergo a gadolinium-enhanced MRI of the brain

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • At least 4 weeks since prior and no concurrent investigational agent
  • No prior stereotactic biopsy
  • At least 30 days since prior drug therapy that has not received regulatory approval for any indication
  • No chemotherapy within the past 5 years
  • No prior chemotherapy for a brain tumor
  • No prior radiotherapy to the head
  • No other concurrent anticancer therapy
  • No concurrent anticoagulation therapy except low-dose prophylactic low molecular weight heparin
  • Concurrent steroid therapy allowed provided patient is on a stable or decreasing dose for ? 1 week
  • At least 14 days since prior and no concurrent enzyme-inducing anticonvulsants (e.g., carbamazepine, phenobarbital, and phenytoin)
  • No concurrent strong inducers or inhibitors of CYP3A4
  • No concurrent planned surgery for other diseases (e.g., dental extraction)
  • No placement of Gliadel® wafer during prior surgery
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 120 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium,   France,   Germany,   Italy,   Netherlands,   Spain,   Switzerland,   United Kingdom
Removed Location Countries Austria
 
Administrative Information
NCT Number  ICMJE NCT01019434
Other Study ID Numbers  ICMJE EORTC-26082-22081
EORTC-26082
EORTC-22081
EU-20987
2008-003003-31 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party European Organisation for Research and Treatment of Cancer - EORTC
Study Sponsor  ICMJE European Organisation for Research and Treatment of Cancer - EORTC
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Study Chair:Wolfgang WickUniversitatsklinikum Heidelberg
Study Chair:Gianfranco Pesce, MDIstituto Oncologico della Svizzera Italiana - Ospedale San Giovanni
PRS Account European Organisation for Research and Treatment of Cancer - EORTC
Verification Date July 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP